The FDA Has Approved Tarsus Pharmaceuticals' Xdemvy (Lotilaner Ophthalmic Solution, Formerly TP-03) 0.25% For Demodex Blepharitis; Xdemvy Expected To Be Available By Prescription By The End Of August 2023
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Tarsus Pharmaceuticals' Xdemvy (Lotilaner Ophthalmic Solution, formerly TP-03) 0.25% for Demodex Blepharitis. The drug is expected to be available by prescription by the end of August 2023.
July 25, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals' Xdemvy has been approved by the FDA, which could potentially increase the company's revenues once the drug is available by prescription by the end of August 2023.
FDA approval is a significant milestone for any pharmaceutical company. It allows the company to market and sell the drug, which can lead to increased revenues. Given that Xdemvy is expected to be available by prescription by the end of August 2023, this could potentially boost Tarsus Pharmaceuticals' revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100